Pyrazolopyridine Derivative Acts as a Novel Cyclooxygenase Inhibitor: Antiplatelet Effect in Aged Patients with Ischemic Stroke

Publisher: John Wiley & Sons Inc

E-ISSN: 1532-5415|42|6|639-642

ISSN: 0002-8614

Source: JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol.42, Iss.6, 1994-06, pp. : 639-642

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Objective: To examine the antiplatelet effect of a novel pyrazolopyridine derivative (KC‐764) in geriatric patients with ischemic stroke.Design: Randomized clinical trial of three graded dose levels.Setting: A geriatric clinic attached to a nursing home.Patients: Fifteen patients with a history of cerebral infarction with a mean age of 75±5 years (range, 65–83). Patients were divided into three groups and administered 10, 20, or 40 mg/day KC‐764 for 8 weeks.Measurements: Platelet aggregation induced by arachidonate, ADP, collagen and platelet‐activating factor. Plasma or serum levels of thromboxane B2 and 6‐ketoprostaglandin F1α.Main Results: Platelet aggregation was inhibited by KC‐764 administration and returned to the control level after discontinuation. Although plasma thromboxane B2 levels were markedly decreased, plasma 6‐ketoprostaglandin F1α was not affected. However, the dose of 10 mg/day was not sufficient to maintain an effective plasma level of KC‐764. There were no side effects or changes in laboratory findings.Conclusions: We confirmed that KC‐764 at a dose of 20 to 40 mg/day is an effective antiplatelet agent and a good candidate for a trial to see if it is feasible for long‐term use for the prevention of ischemic stroke in high‐risk patients.

Related content